<- Go Home
Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Market Cap
$149.2M
Volume
249.4K
Cash and Equivalents
$51.9M
EBITDA
-$49.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$5.31
52 Week Low
$1.84
Dividend
N/A
Price / Book Value
3.48
Price / Earnings
-2.00
Price / Tangible Book Value
3.65
Enterprise Value
$103.8M
Enterprise Value / EBITDA
-2.09
Operating Income
-$50.1M
Return on Equity
120.11%
Return on Assets
-50.63
Cash and Short Term Investments
$55.4M
Debt
$10.0M
Equity
$41.7M
Revenue
N/A
Unlevered FCF
-$21.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium